biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Until March...

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Feb 04, 2023 11:42am

151 Views

Post# 35266766

RE:RE:RE:RE:Until March...

If course it's speculation, G1945V. Duh!

Somebody could step forward and save Bioasis.

Altruism can exist alongside self interest.

Bioasis has signalled that they have enough funds "approximately March 2023." They didn't say until the end of March likely because that would be inaccurate.

Maybe somebody should write the story all out and submit it to regulators. Maybe they'll call a halt on everything. Gotta be done in the next week or two, though.

But we'll know in a month how it all went.

jd

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market